Public Health and the BSE Epidemic

  • M. N. Ricketts
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 284)


Bovine Spongiform Encephalopathy was discovered in 1986 in the United Kingdom and relatively rapidly spread into its trading partners in Europe via contaminated cattle feed supplements. The practice of using the discarded bovine carcass as cattle feed supplements led to the recycling of the prion agent and the consequent generation of new point source epidemics in the recipient countries. The advent of rapid diagnostic tests and more widespread testing has led to the identification of BSE in countries not previously reporting cases and the recognition of larger numbers of infections in countries previously only reporting clinical cases. The recognition of the wider spread of BSE and the 1996 recognition of vCJD as a human disease caused by consumption of BSE agent led to international concerns regarding the threat to human health and the demand for stricter controls on human food derived from cattle. Major shifts in food safety policy have occurred as a direct result. The recommendation that risk assessments for BSE infectivity and human exposure pathways be conducted rather than reliance upon rates and simple enumeration of BSE cases is one of the most prominent changes in the basis of policy regarding human health. The movement of BSE into human populations has a wider impact than seen in food safety—surgical procedures, blood, cells, tissues and organ donation programs are all affected. The World Health Organization has recommended that ‘the eradication of BSE must remain the principle public health objective of national and international animal health control authorities’.

The opinions expressed in this chapter are those of the author and do not necessarily reflect the views of Health Canada. This review was written while the author was employed at the WHO.


Bovine Spongiform Encephalopathy Bovine Spongiform Encephalopathy Case Bovine Spongiform Encephalopathy Agent Scientific Steering Committee Prion Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    EEC Decision 89/469/EEC, 1989Google Scholar
  2. 2.
    Bovine Offal (Prohibition) Regulations 1989 (SI 1989 No 2061), UKGoogle Scholar
  3. 3.
    EEC Decision 90/200/EEC, April 1990Google Scholar
  4. 4.
    Bovine Spongiform Encephalopathy (No.2) Amendment Order 1990 (SI 1990 No 1930), UKGoogle Scholar
  5. 5.
    Proceedings of the Joint WHO/FAO/OIE Consultation on BSE: public health, animal health and trade. Paris, France. June 2002Google Scholar
  6. 6.
    OIE Terrestrial Animal Health Code Chapter 12th Edition, May 2003 Bovine Spongiform Encephalopathy 2003
  7. 7.
    Opinion of the Scientific Steering Committee on the Geographical Risk of Bovine Spongiform Encephalopathy (GBR) SSC/11/0112002/6.2.c.1 adopted 11 January 2002Google Scholar
  8. 8.
    Opinions and Reports from the Scientific Steering Committee 2003
  9. 9.
    UK Food Safety Agency Review of BSE Controls
  10. 10.
    Department of Environment, Food and Rural Affairs (DEFRA) Publications on implementation and regulation 2003
  11. 11.
    Department of Environment, Food and Rural Affairs (DEFRA) Reports from the Spongiform Encephalopathy Advisory Committee
  12. 12.
    Report of the UK BSE Inquiry October 2000, written by the Members of the Committee of the Inquiry, Lord Phillips of Worth Matravers, Mrs June Bridgeman, Professor Malcolm Ferguson-Smith. 2003
  13. 13.
    Report of a WHO Consultation on Public Health Issues related to Human and Animal Transmissible Spongiform Encephalopathies. Document WH/EMC/DIS/ 96.147. Geneva, Switzerland 2–3 April 1996Google Scholar
  14. 14.
    Opinion of the Scientific Steering Committee: Listing of Specified Risk Materials, a scheme for assessing relative risks to man: adopted on 9 September 1997, reedited version adopted by the Scientific Steering Committee during its third Plenary Session of 22–23 January 1998Google Scholar
  15. 15.
    Report of the Gelatine Manufacturers Association, 2003,
  16. 16.
    Hill AF, Butterworth RJ, Jointer S, et al: Investigation of variant Creutzfeldt-Jakob and other human prion diseases with tonsil biopsy samples. Lancet 353: 183–199, 1999PubMedCrossRefGoogle Scholar
  17. 17.
    Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 352: 703–704, 1998PubMedCrossRefGoogle Scholar
  18. 18.
    Ironside JW, Hilton DA, Ghani A, Johnstone NJ, Conyers L, McCardle LM, Best D. Retrospective study of prion-protein accumulation in tonsil and appendix tissues. Lancet 355 (9216): 1693–1694, 2000PubMedCrossRefGoogle Scholar
  19. 19.
    Report of the WHO Consultation on Infection Control Guidelines for Transmissible Spongiform Encephalopathies WHO/CDS/CSR/APH/2000.3 Geneva, Switzerland 24–26 March 1999Google Scholar
  20. 20.
    WHO Guidelines on Transmissible Spongiform Encephalopathies in Relation to Biological and Pharmaceutical Products. WHO/BCT/HTP Geneva, Switzerland, 3–5 February 2003Google Scholar
  21. 21.
    Report of the WHO Consultation on Public Health and Animal TSEs: Epidemiology, risk and research requirements Geneva 1–3 December 1999Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • M. N. Ricketts
    • 1
  1. 1.Health CanadaOttawaCanada

Personalised recommendations